Splunk reported a solid overall fiscal Q4 but the company is targeting fiscal 2021 revenue growth of only 10%, well below the Street's +23% target, Mizuho analyst Gregg Moskowitz tells investors in a research note. The variance is due to an accelerated mix shift to cloud, and management also guided to a much stronger than expected annual recurring revenue of 40% through fiscal 2023, adds the analyst. He maintains that Splunk's value proposition remains significantly differentiated and that the company is well positioned to continue growing at a high rate. Moskowitz keeps a Buy rating on Splunk with a $175 price target.

New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).